Top

Published in:

01-07-2018 | Original Article

Association of IL-27 rs153109 and rs17855750 Polymorphisms with Risk and Response to Therapy in Acute Lymphoblastic Leukemia

Authors: Alireza Ghavami, Gholamreza Fathpour, Zahra Amirghofran

Published in: Pathology & Oncology Research | Issue 3/2018

Abstract

Interleukin (IL)-27 is a cytokine with important anti-cancer activity. This study has evaluated the effects of IL-27 rs153109 and rs17855750 single nucleotide polymorphisms (SNPs) on risk of acute lymphoblastic leukemia (ALL) development, as well as their impact on prognosis and patient survival. A total of 200 patients and 210 healthy subjects were genotyped by polymerase chain reaction-restriction fragment length polymorphism. We observed a higher frequency of rs153109 AG and rs17855750 TG genotypes and allele G in patients compared to controls (p < 0.001). Combined G variant genotypes (AG + GG and TG + GG) also conferred significantly greater risk of ALL. There was a significant correlation between the genotypes of both SNPs with event-free survival (EFS). Patients with GG genotypes of both SNPs and those of rs153109 AG and rs17855750 TG had a shorter EFS than patients with rs153109 AA and rs17855750 TT genotypes (p ≤ 0.035). Combined G variant genotypes for both SNPs showed poorer response to therapy in all patients (p < 0.027) as well as B-ALL (rs153109, p < 0.001) and T-ALL (rs153109, p = 0.048) patients. In multivariate analysis, rs153109 combined G variant genotype was associated with shorter EFS (relative risk = 9.7, p = 0.026). Among those who relapsed, 87.1% had the rs153109 AG genotype and 77.4% had the rs17855750 TG genotype (p < 0.01). Patients had higher IL-27 serum levels compared to controls, but this did not differ between genotypes. In conclusion, the association of IL-27 rs153109 and rs17855750 polymorphisms with risk of ALL development and their impact on EFS suggested an important role for this cytokine in biology and response to ALL therapy.

Available only for authorised users

Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet 1:1943–1955CrossRef

Kamazani FM, Bahoush GR, Aghaeipour M, Vaeli S, Amirghofran Z (2013) CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance. Med Oncol 30:359CrossRefPubMed

Fathi M, Amirghofran Z, Shahriari M (2012) Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol 29:2046–2052CrossRefPubMed

Behzadi P, Behzadi E, Ranjbar R (2016) IL-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and Signalling pathways. Acta Microbiol Immunol Hung 63:1–25CrossRefPubMed

Brombacher F, Kastelein RA, Alber G (2003) Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 24:207–212CrossRefPubMed

Goplen NP, Saxena V, Knudson KM, Schrum AG, Gil D, Daniels MA, Zamoyska R, Teixeiro E (2016) IL-12 signals through the TCR to support CD8 innate immune responses. J Immunol 15:2434–2443CrossRef

Yoshida H, Miyazaki Y, Yoshiyuki M (2008) Regulation of immune responses by interleukin-27. Immunol Rev 226:234–247CrossRefPubMed

Hasegawa H, Mizoguchi I, Chiba Y, Ohashi M, Xu M, Yoshimoto T (2016) Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family. Front Immunol 7:479CrossRefPubMedPubMedCentral

Yoshida H, Hunter CA (2015) The immunobiology of interleukin-27. Annu Rev Immunol 33:417–443CrossRefPubMed

10.

Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal MR, Kastelein RA (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 15:2225–2231CrossRef

11.

Aparicio-Siegmund S, Garbers C (2015) The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev 26:579–586CrossRefPubMed

12.

Owaki T, Asakava M, Fukai F, Mizuguchi J, Yoshimoto T (2006) IL-27 induces Th1 differentiation via p 38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol 177:7579–7587CrossRefPubMed

13.

Wang Q, Liu J (2016) Regulation and immune function of IL-27. Adv Exp Med Biol 941:191–211CrossRefPubMed

14.

Hunter CA, Kastelein R (2012) Interleukin-27: balancing protective and pathological immunity. Immunity 14:960–969CrossRef

15.

Liu Z, Liu JQ, Talebian F, Wu L, Li S, Bai XF (2013) IL-27 enhances the survival of tumor antigen specific CD8(+) Tcells and programs them into IL-10 producing, memory precursor-like effector cells. Eur J Immunol 43:468–479CrossRefPubMedPubMedCentral

16.

Yoshimoto T, Chiba Y, Furusawa J, Xu M, Tsunoda R, Higuchi K, Mizoguchi I (2015) Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci 106:1103–1110CrossRefPubMedPubMedCentral

17.

Liu Z, Yu J, Carson WE, Xue-Feng Bai X (2013) The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res 5:470–480PubMedPubMedCentral

18.

Giuliani N, Airoldi I (2011) Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells. Clin Cancer Res 17:6963–6970CrossRefPubMed

19.

Xu XP, Hua LY, Chao HL, Chen ZX, Wang XF, Ji J, Liu N (2014) Genetic association between IL-27 rs153109 polymorphism and cancer risk in Chinese population: a meta-analysis. J Recept Signal Transduct Res 26:1–6

20.

Zhang S, Wang Y, Wang M, Ji Z (2014) IL-27-964A>G polymorphism and the risk of breast cancer: a case-control study. Tumour Biol 35:12099–12102CrossRefPubMed

21.

Tao YP, Wang WL, Li SY, Zhang J, Shi QZ, Zhao F, Zhao BS (2012) Associations between polymorphisms in IL-12A, IL-12B, IL-12Rβ1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J Cancer Res Clin Oncol 138:1891–1900CrossRefPubMed

22.

Shi J, Yuan M, Liu S, Duan X, Chen J (2016) Correlation of IL-27 genetic polymorphisms with the risk and survival of cervical cancer in a Chinese Han population. Tumour Biol 37:6875–6879CrossRefPubMed

23.

Zhang Z, Zhou B, Wu Y (2014) Prognostic value of IL-27 polymorphisms and susceptibility to epithelial ovarium cancer in a chinese population. Immunogenetics 66:85CrossRefPubMed

24.

Meadows AT, Chintagumpala M, Dunkel IJ, Friedman D, Stoner JA, Villablanca JG (2009) Children’s oncology group trials for Retinoblastoma. In: Singh A, Damato B, Pe’er J, Murphree AL, Perry JD (eds) Essentials of ophthalmic oncology. SLACK Incorporated, Thorofare, pp 204–205

25.

Pizzo PA, Poplack DG, Adamson PC, Blaney SM, Helman LJ (2015) Principles and practice of pediatric oncology, 7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 463–497

26.

Amirghofran Z, Asiaee E, Kamazani FM (2016) Soluble CD44 and CD44v6 and prognosis in children with B-cell acute lymphoblastic leukemia. Asia Pac J Clin Oncol 12:e375–e382CrossRefPubMed

27.

Valibeigi B, Amirghofran Z, Golmoghaddam H, Hajihosseini R, Kamazani FM (2014) Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis. Pathol Oncol Res 20:367–374CrossRefPubMed

28.

Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M (2011) The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia. Arch Iran Med 14:170–174PubMed

29.

Pu Y, Chen P, Zhou B, Zhang P, Wang Y, Song Y, Zhang L (2015) Association between polymorphisms in IL27 gene and renal cell carcinoma. Biomarkers 20:202–205CrossRefPubMed

30.

Lyu S, Ye L, Wang O, Huang G, Yang F, Liu Y, Dong S (2015) IL-27 rs153109 polymorphism increases the risk of colorectal cancer in Chinese Han population. Onco Targets Ther 16:1493–1497CrossRef

31.

Yu X, Zhang Z, Zhou B, Zhang L, Chen P, Duan R, Li L, Zeng X, Xi M (2016) Genetic polymorphisms of interleukin-27 is associated with endometrial cancer susceptibility in Chinese Han women. Int J Clin Exp Pathol 9:2718–2725

32.

Chae SC, Li CS, Kim KM, Yang JY, Zhang Q, Lee YC (2007) Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J Hum Genet 52:355–361CrossRefPubMed

33.

Wang Z, Wang L, Fan R, Zhou J, Zhong J (2014) Association of IL-27 gene three polymorphisms with Crohn’s disease susceptibility in a Chinese Han population. Int J Clin Exp Pathol 7:8952–8957PubMedPubMedCentral

34.

Tang YJ, Wang JL, Nong LG, Lan CG, Zha ZG, Liao PH (2014) Associations of IL-27 polymorphisms and serum IL-27p28 levels with osteosarcoma risk. Medicine (Baltimore) 93:e56CrossRef

35.

Zhou B, Zhang P, Tang T, Liao H, Zhang K, Pu Y, Chen P, Song Y, Zhang L (2015) Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer. BMC Cancer 15:433CrossRefPubMedPubMedCentral

36.

Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ (2009) A novel functional polymorphism, 16974 A/C, in the interleukin-12-3′ untranslated region is associated with risk of glioma. DNA Cell Biol 28:335–341CrossRefPubMed

37.

Zhang J, Qian X, Ning H, Yang J, Xiong H, Liu J (2010) Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J Biol Chem 9:21269–21281CrossRef

38.

Naumnik W, Naumnik B, Niewiarowska K, Ossolin Ska M, Chyczewska E (2012) Novel cytokines:IL-27, IL-29, IL-31: can they be useful in clinical practice at the time diagnosis of lung cancer. Exp Oncol 34:348–353PubMed

39.

Lu D, Zhou X, Yao L, Liu C, Jin F, Wu Y (2014) Clinical implications of the interleukin 27 serum level in breast cancer. J Investig Med 62:627–631CrossRefPubMed

40.

Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107:1696–1704CrossRefPubMedPubMedCentral

41.

Zorzoli A, Di Carlo E, Cocco E, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I (2012) Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/II2rg−/− mice. Clin Cancer Res 18:1630–1640CrossRefPubMed

42.

Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, Ognio E, Sorrentino C, Ribatti D, Zorzoli A, Basso G, Dufour C, Airoldi I (2011) Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 25:1815–1824CrossRefPubMed

Title: Association of IL-27 rs153109 and rs17855750 Polymorphisms with Risk and Response to Therapy in Acute Lymphoblastic Leukemia
Authors: Alireza Ghavami
Gholamreza Fathpour
Zahra Amirghofran
Publication date: 01-07-2018
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0295-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management

Alterations in SCAI Expression during Cell Plasticity, Fibrosis and Cancer

Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study

Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis

Prevalence of Anal Human Papillomavirus Infection in Hungarian Men Who Have Sex with Men

Keynote webinar | Spotlight on antibody–drug conjugates in cancer